Roche Ally Hetero Drugs Beat Ranbaxy, Cipla To Win Oseltamivir Supply Contract From Indian Government
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Hetero Drugs has edged past bigger Indian rivals Ranbaxy and Cipla to bag the government tender floated for supplies of oseltamivir. Hetero received orders to supply nine million capsules of generic versions of Roche's anti-viral brand Tamiflu. The entire contract is believed to be worth $6 to $8 million
You may also be interested in...
Roche In Stand-by Mode To Supply Tamifl& To Indian Government; Others Queue Up Too
MUMBAI - As the Indian government grapples with the threat of influenza H1N1 through countrywide moves to stockpile drugs, protective masks and diagnostic kits, Roche India has said it has been approached for supplies of Tamiflu (oseltamivir) by the Indian health ministry but there are no clear orders issued yet to commence supply of the drugs
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).